These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 7727862)
1. [Resistance associated with the glutathione system]. Gouyette A Bull Cancer; 1994 Dec; 81 Suppl 2():69s-73s. PubMed ID: 7727862 [TBL] [Abstract][Full Text] [Related]
2. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme. Wang W; Liu G; Zheng J Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556 [TBL] [Abstract][Full Text] [Related]
3. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
4. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187 [TBL] [Abstract][Full Text] [Related]
6. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Greenbaum M; Létourneau S; Assar H; Schecter RL; Batist G; Cournoyer D Cancer Res; 1994 Aug; 54(16):4442-7. PubMed ID: 8044793 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N; Lam YM; Pym J; Campling BG Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677 [TBL] [Abstract][Full Text] [Related]
8. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities. Pawlik CA; Israel M; Sweatman TW; Lothstein L Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692 [TBL] [Abstract][Full Text] [Related]
9. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review. Waxman DJ Cancer Res; 1990 Oct; 50(20):6449-54. PubMed ID: 2208103 [No Abstract] [Full Text] [Related]
10. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711 [TBL] [Abstract][Full Text] [Related]
11. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Pandya U; Srivastava SK; Singhal SS; Pal A; Awasthi S; Zimniak P; Awasthi YC; Singh SV Biochem Biophys Res Commun; 2000 Nov; 278(1):258-62. PubMed ID: 11071881 [TBL] [Abstract][Full Text] [Related]
12. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. Paumi CM; Ledford BG; Smitherman PK; Townsend AJ; Morrow CS J Biol Chem; 2001 Mar; 276(11):7952-6. PubMed ID: 11115505 [TBL] [Abstract][Full Text] [Related]
13. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482 [TBL] [Abstract][Full Text] [Related]
14. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612 [TBL] [Abstract][Full Text] [Related]
15. Survival of hematopoietic and lymphoma colony-forming cells in vivo following the administration of a variety of alkylating agents. Valeriote FA; Tolen SJ Cancer Res; 1972 Mar; 32(3):470-6. PubMed ID: 4621955 [No Abstract] [Full Text] [Related]
16. Microsomal glutathione transferase 1 in anticancer drug resistance. Johansson K; Ahlen K; Rinaldi R; Sahlander K; Siritantikorn A; Morgenstern R Carcinogenesis; 2007 Feb; 28(2):465-70. PubMed ID: 16920737 [TBL] [Abstract][Full Text] [Related]
17. Prevention of the development of melphalan resistance in vitro by selenite. Caffrey PB; Zhu M; Frenkel GD Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492 [TBL] [Abstract][Full Text] [Related]
18. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Dirven HA; van Ommen B; van Bladeren PJ Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469 [TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. Chen G; Teicher BA; Frei E Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Harkey MA; Czerwinski M; Slattery J; Kiem HP Cancer Invest; 2005; 23(1):19-25. PubMed ID: 15779864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]